title: Anti-TNF treatment of reactive arthritis. A monocentric experience.
authors.affiliation: CHRU de Besançon, University Teaching Hospital, Department of Rheumatology, 2, boulevard Fleming, 25030 Besançon, France.
authors.forename: Anne
authors.initials: A
authors.lastname: Brinster
authors.affiliation: CHRU de Besançon, University Teaching Hospital, Department of Rheumatology, 2, boulevard Fleming, 25030 Besançon, France.
authors.forename: Xavier
authors.initials: X
authors.lastname: Guillot
authors.affiliation: CHRU de Besançon, University Teaching Hospital, Department of Rheumatology, 2, boulevard Fleming, 25030 Besançon, France.
authors.forename: Clément
authors.initials: C
authors.lastname: Prati
authors.affiliation: CHRU de Besançon, University Teaching Hospital, Department of Rheumatology, 2, boulevard Fleming, 25030 Besançon, France; Université de Franche-Comté, EA 4266, 25030 Besançon, France. Electronic address: dwendling@chu-besancon.fr.
authors.forename: Daniel
authors.initials: D
authors.lastname: Wendling
mesh_terms: D000068879:Adalimumab / Q000008:administration & dosage; D000328:Adult; D016918:Arthritis, Reactive / Q000175:diagnosis / Q000188:drug therapy*; D015331:Cohort Studies; D000068800:Etanercept / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D025241:Spondylarthritis / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept
keywords: Anti-TNF agents; Reactive arthritis; Spondyloarthritis; Treatment